To further strengthen its scientific base for taking metabolomics to population-level screening and to individual consumers, Nightingale Health has formed a Scientific Advisory Board comprised of leading researchers from around the world, renowned for their expertise in population health sciences.

Finland’s Nightingale Health, an innovator in blood-testing technology, today announced that four esteemed population health researchers will join Nightingale’s newly formed Scientific Advisory Board. The four members––Prof. George Davey Smith from University of Bristol (UK), Prof. John Danesh from University of Cambridge (UK), Prof. Eline Slagboom from Leiden University Medical Center (The Netherlands) and Prof. José Ordovás from Tufts University (US)––are world-leading experts of biomarkers and cardiometabolic medicine. The advisory board will further strengthen the company’s scientific foundation for taking metabolomics to population-level screening and individual consumers. They will particularly advice on areas like the causal nature of the biomarkers, applications for early risk prediction and clinical decision support and population-scale screening initiatives.

Taking scientific knowledge to everyone

Nightingale recently launched a consumer blood-testing service, My Nightingale, that aims to make preventive health easy and accessible for everyone. Also, many application areas beyond metabolic diseases are rapidly emerging, such as ageing, diet and molecular health tracking. The advisory board will further support evidence generation for the translation of results from global biobank studies and clinical trials. All the members are already involved with large population health studies beyond Europe and North America, which aligns well with Nightingale’s efforts to enable large-scale metabolic biomarker profiling globally.

“Nightingale's core strategy lies in the intersection of science and preventative health applications. We believe that brings benefits in the form of new scientific findings but simultaneously also help people have healthier lives,” said Teemu Suna, founder and CEO of Nightingale Health.

Global plans underway

Nightingale has been working with some of the largest biobanks in the world. The scientific studies on the company’s blood biomarker panel are set to increase exponentially as efforts to profile the world’s largest biobanks, such as the UK Biobank, Mexico City and South Asia Biobank are well underway.

“We are pleased that these well-renowned scientists will help us strengthen the science emerging from our global biobank initiatives. Nightingale remains committed to taking our innovative biomarker offerings beyond applications for population health research with the strongest possible scientific underpinnings,” said Dr Peter Würtz, Scientific Director and Co-founder at Nightingale Health.

About the Scientific Advisory Board Members

George Davey Smith is a professor of Clinical Epidemiology at the University of Bristol (UK), the director of the MRC Integrative Epidemiology Unit (UK), and the scientific director of the Bristol NIHR Biomedical Research Centre. His research has pioneered the understanding of the causes and alleviation of health inequalities; systematic reviewing and meta-analysis; and the study of population health contributions of molecular genetics. Prof Davey Smith has established and has played a pivotal role in the running of many cohort studies involving detailed clinical and biomarker assessments and has been instrumental in pioneering causal analysis methods in epidemiology.

John Danesh is a professor of Epidemiology and Medicine at the University of Cambridge (UK). He also heads the Department of Public Health and Primary Care and Director of Health Data Research-Cambridge and the founder and director of the British Heart Foundation Cardiovascular Epidemiology Unit, which aims to advance understanding and prevention of cardiovascular disease through population health research. Prof Danesh’s research focuses on understanding the causes, enhancing the prediction, and improving the prevention of chronic diseases worldwide, particularly cardiovascular disease.

Eline Slagboom is a professor of molecular epidemiology at the Leiden University Medical Center in the Netherlands. She is also the head of the Molecular Epidemiology section within the Department of Biomedical Data Sciences. She chairs the Dutch Society for Research on Ageing and is the principal investigator of the Leiden Longevity Study and Fellow at the Max Planck Institute for Biology of Ageing in Cologne in Germany. Her research focuses on genomic, epigenetic and biomarker studies of longevity and age-related diseases.

José M Ordovás is the director of the Nutrition and Genomics Laboratory at the Jean Mayer USDA-Human Nutrition Research Center on Aging at Tufts University, and professor of Nutrition and Genetics at Tufts University. He is a pioneer in the field of nutrigenetics and personalized nutrition. As such, his primary research interests focus on the genetic and epigenetic factors predisposing to cardiometabolic diseases and their interaction with environmental and behavioural factors with particular emphasis on diet and chronobiology. He has carried out multiple large cross-cultural studies to determine cardiovascular risk in populations around the world. Moreover, he conducts carefully controlled randomized clinical trials to bring personalized nutrition to the highest level of scientific evidence.

More about Nightingale’s biomarker analysis service for blood, cord blood, urine and cerebrospinal fluid for researchers, and the My Nightingale blood test and app for individuals.

Contact:

Teemu Suna
CEO, Founder
Nightingale Health Ltd. Helsinki, Finland
Tel. +358 40 196 1669
press@nightingalehealth.com

Nightingale Health

Nightingale Health is a fast-growing global health tech company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. With our pioneering blood-testing services, we provide deep health insights and can measure the effects of lifestyle interventions that are invisible in standard lab tests. The deep knowledge fuels scientific discoveries, industry developments, and encourages people to make positive lifestyle changes that take their health forward.